Cancer / Blood Disorders
Julie R. Park, MD
Program Director, Hematology/Oncology Education, Seattle Children's Hospital
Associate professor of Pediatrics, UW School of Medicine
Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center
Dr. Julie R. Park joined Seattle Children's Hospital in 1996. Dr. Park is an active member of the Children's Oncology Group (COG) Consortium, coordinating Fred Hutchinson Cancer Research Center's participation in clinical trials for treatment of neuroblastoma and non-Hodgkin lymphoma, and providing leadership for development of neuroblastoma clinical research within COG. Park's primary focus has been investigating new chemotherapy combinations for the initial treatment of high-risk neuroblastoma, a rare but aggressive form of childhood cancer. She has conducted a multi-center clinical trial to determine the feasibility and toxicity of adding topotecan and cyclophosphamide to intensively dosed standard induction agents. She is collaborating to optimize the use of radiation therapy as part of treatment for neuroblastoma. Park's work has led to the development of a national randomized phase III trial within COG for treatment of newly diagnosed high-risk neuroblastoma.
Dr. Park has steered Seattle Children's into becoming a leading participant in the Phase I Consortium of COG and the New Approaches to Neuroblastoma Therapy Consortium. She has been actively involved in the development of novel chemotherapeutic agents that may block critical tumor cell pathways necessary for tumor cell growth and survival. Her research has also focused on developing molecular approaches to optimize the effectiveness of current chemotherapy agents. She is collaborating on an investigation of a possible relationship between a patient's ability to break down chemotherapy agents and activity against their tumor or risk for development of severe side effects.
Board Certified: Pediatric Hematology-Oncology
Medical School: University of Vermont College of Medicine, Burlington
To schedule an interview with Dr. Park, please contact the Public Relations department.
Blythe G. Thomson, MD
Attending Physician, Seattle Children's Hospital
Clinical Associate Professor, UW School of Medicine
Dr. Blythe Thomson joined Seattle Children's Hospital in 2003. Locally, she serves on the Human Subjects Protection Advisory Committee, the Department of Pediatrics Recognition Committee, the Scientific Advisory Committee of the General Clinical Research Center, Ambulatory Oversight Committee and Institutional Biosafety Committee of the Seattle Cancer Care Alliance. Dr. Thomson is a member of the Children's Oncology Group (COG) Stem Cell Transplant Steering Committee, the Institutional Performance Monitoring Committee and the Accreditation Committee of the Foundation for Accreditation of Cellular Therapies. Her clinical and research interests include bone marrow transplant and leukemia research. She is taking a leading local role on several research projects for the treatment of leukemia, including the Interfant study for infant Acute Lymphoblastic Leukemia (ALL) and research studies for newly diagnosed pre-B-cell leukemia. She is a member of the Therapeutic Advances in Childhood Leukemia consortium to investigate novel therapies for relapsed and refractory leukemia. Additionally, Dr. Thomson is the local investigator for industry-sponsored trials for relapsed leukemia.
Board Certified: Pediatric Hematology-Oncology; Pediatrics
Medical School: Ohio State University College of Medicine, Columbus
Residency: Children's Hospital, Columbus
Fellowship: Fred Hutchinson Cancer Research Center, Seattle
To schedule an interview with Dr. Thomson, please contact the Public Relations department.
Douglas S. Hawkins, MD
Associate Division Chief, Pediatric Hematology/Oncology, Seattle Children's Hospital
Associate Professor of Pediatrics, UW School of Medicine
Dr. Douglas Hawkins joined Seattle Children's Hospital in 1996. Dr. Hawkins is the principal investigator for Children's Oncology Group (COG) activity at Seattle Children's, associate editor of the Journal of Pediatric Hematology/Oncology and vice chair of the COG Soft Tissue Sarcoma Committee. He is a member of several COG committees, including the soft tissue sarcoma, bone tumor, and voting body steering committees. Dr. Hawkins has focused on clinical research, particularly in the treatment of pediatric sarcomas. He is the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma, and vice chair of three other COG clinical trials. He is collaborating on a pharmacogenomic study investigating cyclophospharmide metabolism and toxicity, both locally and as part of two COG studies. In addition, he collaborates on the use of the fluorodeoxyglucose positron emission tomography (FDG-PET) scan to assess response and guide treatment in pediatric sarcomas.
Board Certified: Pediatric Hematology-Oncology
Medical School: Harvard Medical School, Boston
Residency: University of Washington, Seattle
To schedule an interview with Dr. Hawkins, please contact the Public Relations department.